Akebia Therapeutics

AKBA

Market cap $359M

AKBA Hedge Fund Activity: Q1 2026 in Review

171 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2026, worth a combined $141M — down 26% from $190M a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new AKBA positions and 27 closed out — a net gain of 10 holders — while 41 added to existing stakes and 53 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $1.66M. The largest seller was Citadel Advisors, cutting an estimated $4.5M.

• 171 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2026, up from 165 in Q4 2025.
• Funds reported $141M of Akebia Therapeutics stock for Q1 2026, down 26% quarter-over-quarter.
• 37 funds opened new Akebia Therapeutics positions in Q1 2026 and 27 closed out, a net change of +10 holders.
• The largest Akebia Therapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $1.66M added.
• The largest Akebia Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $4.5M sold.

Based on aggregated 13F filings for Q1 2026.